Does dbvt stock pay dividends?
DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France. More... DBVT does not currently pay a dividend.
What are analysts' price targets for DBV Technologies (DBV)?
3 analysts have issued 12-month price targets for DBV Technologies' shares. Their forecasts range from $7.00 to $8.00. On average, they anticipate DBV Technologies' stock price to reach $7.50 in the next twelve months. This suggests a possible upside of 41.2% from the stock's current price.
What is the upside for DBV Technologies' stock?
On average, they anticipate DBV Technologies' stock price to reach $7.50 in the next twelve months. This suggests a possible upside of 41.2% from the stock's current price. View analysts' price targets for DBV Technologies or view top-rated stocks among Wall Street analysts.
Should I buy or sell DBV Technologies stock right now?
5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for DBV Technologies in the last year. There are currently 3 hold rat...
What is DBV Technologies' stock price forecast for 2022?
5 Wall Street research analysts have issued 12-month price targets for DBV Technologies' shares. Their forecasts range from $1.50 to $10.00. On ave...
How has DBV Technologies' stock performed in 2022?
DBV Technologies' stock was trading at $1.60 at the beginning of the year. Since then, DBVT stock has increased by 72.5% and is now trading at $2.7...
When is DBV Technologies' next earnings date?
DBV Technologies is scheduled to release its next quarterly earnings announcement on Monday, August 1st 2022. View our earnings forecast for DBV T...
How were DBV Technologies' earnings last quarter?
DBV Technologies S.A. (NASDAQ:DBVT) issued its earnings results on Sunday, August, 1st. The company reported ($0.28) earnings per share for the qua...
Who are DBV Technologies' key executives?
DBV Technologies' management team includes the following people: Mr. Daniel Tassé , CEO & Director (Age 62, Pay $1.1M) Mr. Sébastien Robitaille...
Who are some of DBV Technologies' key competitors?
Some companies that are related to DBV Technologies include ImmunityBio (IBRX) , Revolution Medicines (RVMD) , Iovance Biotherapeutics (IOVA) ,...
What other stocks do shareholders of DBV Technologies own?
Based on aggregate information from My MarketBeat watchlists, some companies that other DBV Technologies investors own include Aimmune Therapeutic...
What is DBV Technologies' stock symbol?
DBV Technologies trades on the NASDAQ under the ticker symbol "DBVT."
What is DBV technology?
What is the P/B ratio of DBV?
DBV Technologies SA is a clinical-stage biopharmaceutical company, which engages in the research and development of epicutaneous immunotherapy products. The firm focuses on the development of Viaskin, an electrostatic patch, which may offer a convenient, self-administered, and non-invasive immunotherapy to patients. It also designs a robust clinical development program that includes ongoing clinical trials of Viaskin peanut, and Viaskin milk, as well as pre-clinical development of Viaskin egg. The company was founded by Pierre-Henri Benhamou, Stéphane Benhamou, Bertrand Dupont, Christophe Dupont, and Pierre-Yves Vannerom on March 29, 2002 and is headquartered in Montrouge, France.
Does DBV pay dividends?
DBV Technologies has a P/B Ratio of 2.76. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.
Transparency is our policy. Learn how it impacts everything we do
DBV Technologies does not currently pay a dividend.
How we make money
Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.
How we use your personal data
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management.
How we approach editorial content
How we use your information depends on the product and service that you use and your relationship with us. We may use it to: